UCL: Lookman Benched In Atalanta’s Big Win, Tella Features For LeverkusenThe Maple Leafs earned an impressive 5-2 victory over the Detroit Red Wings , spoiling Todd McLellan’s debut behind the bench for Detroit. David Amber and the Hockey Central panel—featuring Justin Bourne, Elliott Friedman, and more—broke down Mitch Marner’s incredible three-goal performance, highlighting the game. Their analysis shed light on how the Maple Leafs overcame the absence of their captain, Auston Matthews, and the toll taken on their battered blue line. Marner Put Up His 18th Multiple-Point Game of the Season Last Night David Amber praised Marner’s standout performance, noting it was his 18th multi-point game of the season—a career-high for the talented forward. With Matthews out of the lineup, Marner rose to the occasion, delivering when the team needed him most. Amber highlighted how this performance exemplifies Toronto’s ability to win critical games, even under challenging circumstances. The panel also pointed out key plays from John Tavares and William Nylander, whose creativity and skill set up crucial goals. Marner’s leadership in stepping up offensively was a critical factor in the win. Maple Leafs Defensive Sacrifices Take a Toll Elliott Friedman focused on the Maple Leafs’ blue line, which endured a punishing night. Injuries and painful blocks left several defensemen bruised, including Morgan Rielly and Simon Benoit. Friedman emphasized the physical sacrifices made by the team, noting that these games can be particularly gruelling during back-to-back schedules. One key moment involved Matthew Knies, who took a late-game hit that raised concerns about his availability moving forward. The panel stressed the importance of these sacrifices and acknowledged the challenges ahead as the Maple Leafs head into a tougher matchup tonight against the Washington Capitals. Detroit’s Struggled Under New Coach Todd McLellan While the Maple Leafs shone, the Red Wings failed to capitalize on the supposed spark of a coaching change. The panel noted that McLellan’s first game behind the bench was underwhelming, as Detroit came out flat despite their four-game losing streak. Friedman commented on the team’s lack of energy and cohesion, pointing out that McLellan’s immediate focus will likely be rebuilding individual confidence rather than implementing sweeping system changes. Justin Bourne humorously noted the players’ reliance on iPads on the bench, likening it to trying to calm distracted kids. The Red Wings’ inability to respond to adversity was glaring, leaving McLellan with plenty of work. A Hard-Fought Maple Leafs Win with Lingering Questions The Maple Leafs’ victory highlighted the work ethic of their star players, particularly Mitch Marner, who continues to elevate his game. However, the toll taken on their blue line raises concerns about sustainability during a tough schedule. As for the Red Wings, McLellan’s debut behind the bench didn’t provide the jolt the team desperately needed. The panel speculated that Detroit’s issues run deeper than coaching, with players needing to find their competitive edge. Looking ahead, the Maple Leafs face a challenging test tonight against the Washington Capitals, with Alex Ovechkin expected to return to the lineup. Can the Maple Leafs maintain their momentum and physical edge against a more challenging opponent? Tonight will tell. This article first appeared on NHL Trade Talk and was syndicated with permission.
Video: NY prison guards beat Robert Brooks from moment he arrived. He died 6 hours later
The 2024 War on the Rocks Holiday Reading ListInvestors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals REGN . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga 's options scanner spotted 12 uncommon options trades for Regeneron Pharmaceuticals. This isn't normal. The overall sentiment of these big-money traders is split between 58% bullish and 41%, bearish. Out of all of the special options we uncovered, 8 are puts, for a total amount of $735,359, and 4 are calls, for a total amount of $167,575. Expected Price Movements After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $700.0 and $800.0 for Regeneron Pharmaceuticals, spanning the last three months. Insights into Volume & Open Interest Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale activity within a strike price range from $700.0 to $800.0 in the last 30 days. Regeneron Pharmaceuticals Call and Put Volume: 30-Day Overview Largest Options Trades Observed: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume REGN PUT SWEEP BEARISH 05/16/25 $78.7 $78.3 $78.7 $780.00 $173.0K 102 22 REGN PUT SWEEP BULLISH 12/19/25 $60.0 $58.3 $58.3 $700.00 $104.9K 210 103 REGN PUT SWEEP BULLISH 12/19/25 $60.0 $57.9 $57.9 $700.00 $98.4K 210 103 REGN PUT SWEEP BULLISH 12/19/25 $60.0 $57.9 $57.9 $700.00 $92.6K 210 103 REGN PUT SWEEP BULLISH 12/19/25 $60.0 $58.3 $58.3 $700.00 $81.6K 210 103 About Regeneron Pharmaceuticals Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). In light of the recent options history for Regeneron Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance. Regeneron Pharmaceuticals's Current Market Status With a trading volume of 444,007, the price of REGN is down by -0.82%, reaching $743.4. Current RSI values indicate that the stock is may be oversold. Next earnings report is scheduled for 66 days from now. What The Experts Say On Regeneron Pharmaceuticals Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1116.2. Turn $1000 into $1270 in just 20 days? 20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access .* An analyst from Truist Securities has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1126. * An analyst from Citigroup downgraded its action to Neutral with a price target of $895. * Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1215. * Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1195. * In a cautious move, an analyst from Wolfe Research downgraded its rating to Outperform, setting a price target of $1150. Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely. If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Almost the first feeling that I have as an Indian towards our late prime minister Dr Manmohan Singh is one of profound guilt: We as people were extremely unfair to the sensitive, suave leader who was all things except one — a politician. And our betrayal of him came when he most needed his people to know how the people of tomorrow’s India matter more than today’s politics and politicians. It should always haunt the conscience of our nation that we allowed the worthiest incumbent to be called an “accidental prime minister”. Or perhaps it was a reflection of our own priorities that virtues such as integrity and humility appeared as “accidents” to us. In a country where corruption, political rowdyism and megalomania pass for “political strength and stature of a leader”, Dr Singh’s self-effacing refusal to demand and hog the limelight were sure to puzzle his country, especially the press and politicians, and the people. To those for whom their own ugly disdain for decency, culture and unpretentious honesty is the new “normal”, Dr Singh’s unassuming insistence on modesty, quiet efficiency and professional integrity were bound to appear as “accidental”. Dr Singh never claimed credit for achievements My memories of Dr Singh are of a person for whom doing the right thing the right way was the only normal way to do anything. No surprises then that he never claimed credit either for his path-breaking economic reforms or for his absolute insistence on administrative efficiency, transparency and accountability. For him, this was the only “normal” way a government could and should function. I am not surprised then that his media adviser felt uncomfortable working for a prime minister who believed that the news needed no “doctoring” and that the media could not be dishonest and therefore required no goading or “management”. I was fortunate that I worked with a leader who shared Dr Singh’s approach to and respect for the media and allowed his adviser to function as an adviser rather than a manipulator of public opinion. So, I was never made to think of him as an “accidental” leader. But I think Dr Singh must have been a media adviser’s worst nightmare. He always preferred me to address him as “Doctor Saab” rather than “PM Saab”. I once asked him how he felt being described as an accidental PM by his own adviser. His response was typically respectful of his former aide: “Perhaps, he was trying to be helpful. He probably thought accidents make better news than prime ministers.” Bond between Dr Singh and Badal Saab One of the great memories of my own professional career centres around being a close witness to an incident of amazing sensitivity involving the relationship between two truly great leaders – Dr Manmohan Singh and Parkash Singh Badal. Both shared much more than the background of a common religious faith and a common ancestral state. Both were humble and modest about their own achievements. Both had a distaste for the high-profile and spotlight – and both were passionate about rural development, health and education, especially the education of the girl child. And both were gentlemen in politics, born democrats and extremely respectful of the Opposition. For both, consensus rather than confrontation was the essence of politics, especially in a country where federal approach is the only way to address issues of diversity. Both were at once devotees as well as champions of dignified decorum in public life. And even while being devoutly religious, both believed in the power of religion to function as a binding glue rather than a divisive potion injected with fanatical poison. For both, peace and communal harmony remained cardinal principles of politics and religious faith. Sympathetic to Punjab, Sikh community Whenever the issues of Punjab and the Sikh community came up for discussion, Badal Saab found a most sympathetic heart and ears waiting for him on the other side of the table. Two instances come immediately to my mind. One: The then chief minister Captain Amarinder Singh was on a personal rampage to decisively finish the political career of Parkash Singh Badal. He and Akali stalwart Gurcharan Singh Tohra had personal grouses to settle with Badal and he was not averse to taking the Congress government’s help to achieve his goals. As election to the 2002 Shiromani Gurdwara Parbandhak Committee (SGPC) executive poll drew closer, the holy city of Amritsar turned khaki and the police entered Harmandar Sahib to block the Badal supporters from voting. Dr Singh saw this as a dangerous development in Sikh politics, fraught with dangers for Punjab and the country. It was an unsolicited but firm prime ministerial intervention by Dr Singh which stopped Captain Amarinder dead in his tracks, and normalcy was restored. I recall Badal Saab personally thanking Dr Singh much later for his intervention. Dr Singh’s response was typically modest and understated: “Oh, I am glad it was resolved. These things must never happen.” Badal Saab was touched to tears by the then prime minister’s modesty. Foiled bid to weaken SGPC The second instance was when the Congress government in Haryana launched a dangerous course to split and weaken the apex Sikh religious body, the SGPC, by bifurcating it with a separate body in that state. It was and it is a step that can come back to haunt the country. And all this just for petty political gains. A divided Sikh community is not the best recipe for stability in Punjab nor is it in the larger and long-term interests of the country as a whole. No one understood this better than Dr Singh. When Badal Saab broached the subject with Dr Singh in his office, I watched the late PM go silent, profound pain and anxiety writ large on his face. Soon, he would emerge as if from the depths of anguished soul to speak in his trademark gentle voice: “Badal Saab, please relax. This won’t happen, not as long as I am in this office.” And then, almost as an afterthought, he added: “My father took part in ‘Jaitu da morcha’ and other movements to set up the SGPC.” Each in his own right, Dr Singh and Badal Saab were unquestionably the tallest leaders of the era and the undefined and unspoken bond between the two kept Punjab free of needless turmoil for over two decades. Nothing would sum up this silent emotional fibre of their relationship better than an incident that happened at the peak of the Lok Sabha polls in 2009. Both leaders were slated to campaign against each other in Punjab. We were in Amritsar when the news of Dr Singh’s impending surgery was flashed on my laptop. When I passed the news to Badal Saab, he was immediately on line with the PMO to inquire about the PM’s health. Minutes afterwards, he told me he would start “akhand path” at Harmandar Sahib for Dr Singh’s successful surgery and speedy recovery. Badal Saab remained in Amritsar all three days of the “akhand path”. Will this remain a mere nostalgia or will our country ever return to this era of dignified democracy wherein political opposition is merely an expression of alternative paths to the promotion of the national interest and the people’s welfare? Dr Manmohan Singh leaves us at a time when we were just beginning to realise how unfair we had been to him – and exactly when we needed him the most. (The author is a freelance writer and was adviser to former CM Parkash Singh Badal)
At just 21 years old, Madison Feehan, an Edmonton native, is already making significant strides in space exploration through her work with NASA. Her fascination with the cosmos began in ninth grade, and over the last five years, Feehan has progressively honed her expertise, even serving as an executive panelist and peer reviewer for NASA’s Proposal Integrated Review and Evaluation System (NSPIRES). Her role involves evaluating technological concepts for their potential to be utilized in space and their relevance to upcoming NASA missions. Feehan’s dedication extends to her own entrepreneurial venture, Space Copy, where she is the CEO and founder. This innovative company focuses on developing 3D printers capable of fabricating scalable infrastructure in extreme environments both on Earth and in space. By utilizing on-site materials for 3D printing, the company aims to significantly reduce the costs associated with transporting materials for space missions. Space Copy has recently made breakthroughs in converting lunar soil into usable structures, such as bricks, for building habitats, launch pads, roads, and precision tools. The company showcased a 3D printed brick made from lunar soil stimulant, which is 99.7% accurate to material recovered during the Apollo 16 mission. This innovation not only promises to make living in space more feasible but also offers staggering cost reductions, projecting up to a 70% decrease in expenses. In recognition of her groundbreaking work, Feehan has participated in over 60 global conferences in the past two years. Her company was also honored with the Buzz Aldrin Family Foundation Global Innovation Award. Looking forward, Space Copy plans to deploy a 3D printer on the moon by 2031, in conjunction with NASA’s Artemis mission. Despite her young age, Feehan and her team have rapidly advanced in an industry that remains particularly challenging, especially for young women.Stock market today: Wall Street slips as the 'Magnificent 7' weighs down the market
NoneBrock Purdy will miss Sunday's game for the 49ers with a shoulder injuryRaymond J. de Souza: ‘Blue Bloods’ — the unapologetic pro-police drama in an anti-police age